Todos os estudos
RecrutamentoConfirmatório terapêutico (Fase III)Intervencionista

An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years with Late-onset Pompe Disease

Pompe disease is a rare genetic condition where the body cannot break down a complex sugar called glycogen. Over time, this builds up and causes muscle weakness, trouble walking, and breathing difficulties. Late-onset Pompe disease can appear at any time during childhood or adult life. This Phase 3 clinical trial tests a new combination treatment: an enzyme replacement called cipaglucosidase alfa given into a vein, and a liquid medicine called miglustat taken by mouth to help it work better. The study focuses on children and young people aged under 18. Doctors want to check that the medicine is safe, monitor any side effects, and see how well the body absorbs it. They will also measure whether it helps children walk farther, climb stairs more easily, and breathe more strongly. Everyone in the trial receives the study medicine.

Em resumo

Status
Recrutamento
Fase
Confirmatório terapêutico (Fase III)
Patrocinador
Amicus Therapeutics Inc.
Meta de inscrição
9
Iniciar
24 Out 2023

Sobre o que é este estudo?

Pompe disease is a rare, inherited condition caused by a missing or faulty enzyme. Without this enzyme, a type of sugar called glycogen builds up inside the body's cells, particularly in the muscles. Over time, this causes muscle weakness, making everyday activities like walking, running, climbing stairs, or even breathing more difficult. Late-onset Pompe disease usually develops after the first year of life and can affect children, teenagers, and adults.

Currently, treatments aim to replace the missing enzyme, but researchers are looking for ways to make these treatments work more effectively. This clinical study is testing a two-part medicine. The first part is cipaglucosidase alfa, which replaces the missing enzyme and is given through a drip into a vein. The second part is miglustat, a liquid taken by mouth that helps protect the enzyme so it can reach the muscles where it is needed most.

This trial is important because it looks specifically at children and young people under the age of 18. Doctors want to understand how the medicine behaves in growing bodies, check that it is safe, and find out whether it can help protect or improve muscle power and lung function over time. The findings could help provide better treatment options for young people living with this lifelong condition.

Pontos principais

  • Tests a two-part treatment designed to help muscles in children with late-onset Pompe disease.
  • Open to children and young people aged from birth up to 17 years.
  • All participants receive the study medicines; there is no placebo.
  • Tests will check safety, walking, muscle strength, and lung function over 52 weeks.
  • Taking part is voluntary, and you can withdraw at any time.

Quem pode ser elegível?

This study is designed for children, teenagers, and infants from birth up to 17 years of age who have been diagnosed with late-onset Pompe disease. Both boys and girls can take part.

Because this is a specialised study, doctors will need to confirm the diagnosis through genetic testing or enzyme level checks. Depending on the child's age and ability, they may need to be able to do simple walking or movement tests to help measure their progress.

Children may not be able to take part if they have other major medical conditions that could make the trial unsafe, or if they are taking certain other medicines that might interfere with the study. The study doctor will review each child's full medical history with their family before deciding if the study is suitable.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. My child is aged between 0 and 17 years.
  2. My child has a confirmed diagnosis of late-onset Pompe disease.
  3. We are able to travel to study clinic visits for regular treatments and tests.
  4. My child does not have other unrelated severe health conditions that prevent participation.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

Taking part involves receiving regular treatments and attending hospital visits. Children will take miglustat as a liquid medicine by mouth, followed by an infusion (drip into a vein) of cipaglucosidase alfa. These visits usually happen at a specialist hospital clinic.

During visits, the care team will monitor your child's health closely. Assessments include routine blood and urine tests, heart checks (ECGs), and checking vital signs like blood pressure and temperature. Depending on the child's age, researchers will also test walking distance over six minutes, time taken to climb stairs or stand up from a chair, general muscle strength, and lung capacity. The main part of the study lasts for at least 52 weeks (one year), with regular follow-up checks throughout.

Riscos e benefícios potenciais

The treatment may help slow down muscle weakness, support breathing, or improve daily movement, though these benefits cannot be guaranteed. However, all medicines carry risks. Children might experience side effects from the study drugs or infusion reactions, such as fever, chills, rash, or tiredness during or after the drip. Hospital visits also involve blood tests, which can cause brief discomfort or bruising. The study team will watch your child very closely to manage any side effects quickly. Taking part is completely voluntary, and parents or guardians can withdraw their child from the study at any point without affecting their usual NHS care.

Localizações (2)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Itália
  • —
    Não verificado
    Alemanha

Perguntas frequentes

What is the difference between early-onset and late-onset Pompe disease?

Early-onset Pompe disease starts in early infancy and severely affects the heart. Late-onset Pompe disease appears later in infancy, childhood, or adulthood, mainly causing muscle weakness and breathing problems without severe heart disease.

Will my child definitely receive the study medicine?

Yes. This is an 'open-label' study, which means there is no dummy drug (placebo). Every child who takes part receives the active combination treatment.

How is the study treatment given?

Miglustat is a liquid swallowed by mouth. Cipaglucosidase alfa is given shortly afterwards as an intravenous infusion (a slow drip directly into a vein).

Quanto tempo dura o estudo?

The main part of the study tracks health changes over 52 weeks (about one year), with regular treatment visits and check-ups during that time.

Can we leave the study if we change our minds?

Yes. You and your child can leave the trial at any time, for any reason. Your child's normal medical care will continue as usual.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "An Open-label Study of the Safety, Pharmacokinetics, Efficac…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.